Related Experiment Video
Updated: May 18, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Influence of study sponsorship on head and neck cancer randomized trial results
Gordon H Sun1, Jeffrey J Houlton, Mark P MacEachern
1Robert Wood Johnson Foundation Clinical Scholars, University of Michigan, Ann Arbor, Michigan; VA Center for Clinical Management Research, VA Ann Arbor Healthcare System, Ann Arbor, Michigan; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, Ann Arbor, Michigan.
Background:
The purpose of this study was to identify associations between study sponsorship and the methodological quality and published outcomes of head and neck cancer randomized controlled trials (RCTs).
Methods:
We systematically searched MEDLINE, EMBASE, CINAHL, and the Cochrane Central Register of Controlled Trials for qualified RCTs, evaluating journal impact factor (IF), Jadad score (measure of study quality), and results favoring or not favoring experimental therapy.
Results:
Of 118 RCTs, the most common sponsor was government (38; 32%), followed by nonprofit organizations (30; 25%) and industry (26; 22%). Industry-supported RCTs were associated with publication in journals with higher IF compared with RCTs without industry support (p = .013). Government-supported RCTs were associated with higher mean Jadad score (p = .026) and results favoring experimental therapy (p = .034).
Conclusions:
Government-supported, but not industry-supported, RCTs were significantly associated with positive study results. These findings may be confounded by broadly applied definitions of sponsorship.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Longitudinal Research
Blinding
Cancer Survival Analysis
Bioavailability Study Design: Healthy Subjects Versus Patients

